Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Tuberculosis (TB)” report has been added to ResearchAndMarkets.com’s offering.
This Market Spotlight report covers the Tuberculosis (TB) market, comprising key marketed and pipeline drugs, clinical trial…
DUBLIN–(BUSINESS WIRE)–The “US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026” report has been added to ResearchAndMarkets.com’s offering.
The US cancer biosimilar market landscape is inclined towards ent…
A major step toward realizing a groundbreaking new treatment method for hypertension — the first of its kind in Japan
TOKYO–(BUSINESS WIRE)–#CureApp–CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter “the Company”) has complet…
A major step toward realizing a groundbreaking new treatment method for hypertension — the first of its kind in Japan
TOKYO–(BUSINESS WIRE)–#CureApp–CureApp, Inc. (Head Office: Chuo-ku, Tokyo; CEO: Kohta Satake; hereafter “the Company”) has complet…
– New expansion cohorts to be added to ongoing STELLAR-001 trial following dose-escalation phase –
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darm…
– New expansion cohorts to be added to ongoing STELLAR-001 trial following dose-escalation phase –
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darm…
SYDNEY–(BUSINESS WIRE)–Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial on the advice of the study’s clini…
SYDNEY–(BUSINESS WIRE)–Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announced that Veyonda has been approved to move into the second and final stage of the NOXCOVID-1 clinical trial on the advice of the study’s clini…
– Dr. Kasibhatla brings deep drug development expertise across multiple mechanisms of action and therapeutic modalities, as well as a strong foundational understanding of tumor-intrinsic and immuno-oncology targets, to Boundless Bio –
SAN DIEGO–(BUSI…
– New expansion cohorts to be added to ongoing STELLAR-001 trial following dose-escalation phase –
ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darm…